A clinical trial (NCT04027647), carry out by National Cancer Centre, Singapore, is ongoing to verify the efficacy of dacomitinib with 30 mg OD as first‐line treatment in EGFR‐mutated NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.